We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies

By HospiMedica International staff writers
Posted on 10 Feb 2021
A new DVD technology-based system quickly and inexpensively detects SARS-CoV-2 antigens and specific antibodies.

Researchers from the Polytechnic University of Valencia (Valencia, Spain) have developed a new system at laboratory scale that allows a rapid, cheap and effective detection of COVID-19. The system consists of a biosensor based on DVD technologies, that detects specific antibodies (G, M and A) and SARS-CoV-2 antigens - differentiating them to those of influenza - in a safe way, in less than 30 minutes, by analyzing serum or saliva samples. The price of the test is estimated at less than two Euros.

Image: DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies (Photo courtesy of Polytechnic University of Valencia)
Image: DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies (Photo courtesy of Polytechnic University of Valencia)

Called COMBO-SARS-CoV-2, the system can analyze up to a total of six serum and saliva samples simultaneously, determining type G, M and A antibodies and virus-specific antigens in less than half an hour. When a patient tests positive, the serological and/or saliva sample generates an optical signal that allows the identification of individuals who have suffered or are suffering the infection and establishes the concentration of the specific biomarkers. The COMBO-SARS-CoV-2 system can also be applied to detect other agents with infective capacity such as influenza viruses, adenoviruses and respiratory syncytial virus.

“The developed system will allow a rapid and automated viral diagnosis, at a much lower cost than the kits currently in use. Furthermore, these biosensors will enable a practical and efficient monitoring of the level of neutralizing antibodies once the vaccine is ready,” said Sergi Morais, Professor in the Department of Chemistry.

Related Links:
Polytechnic University of Valencia


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Fetal and Maternal Monitor
F9 Series
New
LED Examination Lamp
Clarity 50 LED

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles